Document is current
Any future updates will be listed below
-
Authors
Malard, Florent https://orcid.org/0000-0002-3474-0002
Peric, Zinaida
Ruggeri, Annalisa https://orcid.org/0000-0002-7261-2765
Gedde-Dahl, Tobias
Bazarbachi, Ali https://orcid.org/0000-0002-7171-4997
Ciceri, Fabio
Mehra, Varun
Blaise, Didier
Kinsella, Francesca https://orcid.org/0000-0002-6022-2567
Schoemans, Helene https://orcid.org/0000-0002-7568-8239
Sanz, Jaime
Bonifazi, Francesca https://orcid.org/0000-0003-1544-9911
de Witte, Moniek https://orcid.org/0000-0001-7470-2994
Morsink, Linde
Duarte, Raphael https://orcid.org/0000-0002-5240-9815
Spyridonidis, Alexandros https://orcid.org/0000-0003-3097-2532
Tavori, Guy
Greinix, Hildegard T.
Nagler, Arnon
Holler, Ernst https://orcid.org/0000-0003-2295-2187
Zeiser, Robert https://orcid.org/0000-0001-6565-3393
Mohty, Mohamad https://orcid.org/0000-0002-7264-808X
- License Information
-
More Information
Article History
Received: 24 December 2025
Revised: 22 January 2026
Accepted: 25 February 2026
First Online: 7 March 2026
Competing interests
: FM reports lecture honoraria from Sanofi, Novartis, BMS, Astrazeneca, Therakos, Priothera, MSD and Jazz Pharmaceutical all outside the submitted work. MV reports speaker honoraria from Novartis, Celgene, Gilead, Pfizer, Incyte, Jazz Pharma, Sanofi and Mundipharma, Therakos, advisory board honoraria from Gilead, Pfizer, Sanofi, Mundipharma and Therakos and research grants from Gilead, MSD, Pfizer and MRC. MM reports grants and lecture honoraria from Janssen, Sanofi, Maat Pharma and JAZZ Pharmaceuticals, lecture honoraria from Celgene, Amgen, BMS, Takeda, and Pfizer, grants from Roche, all outside the submitted work. The other authors declare no competing financial interests.
